Technical Report No. 67

Exclusion of Objectionable Microorganisms from Nonsterile Pharmaceuticals, Medical Devices, and Cosmetics

2014

PDA®
Parenteral Drug Association
PDA Exclusion of Objectionable Microorganisms from Nonsterile Pharmaceuticals, Medical Devices, and Cosmetics Technical Report Team

Authors

Anil Sawant, Ph.D., Johnson & Johnson (Co-chair)
Anthony M. Cundell, Ph.D., Consultant (Co-chair)
Donald G. Ahearn, Ph.D., Georgia State University
Matthew J. Arduino, M.S., Dr.P.H., Centers for Disease Control and Prevention
Julie Barlasov, MBA., Perritt Laboratories
Mark Dato, M.D., Ph.D., Procter & Gamble
Andrew Dick, Johnson & Johnson
Donald J. English, Avon Products, Inc.
Rhonda Ezell, Qualitest Pharmaceuticals
Dennis E. Guilfoyle, Ph.D., Food and Drug Administration
David Hussong, Ph.D., Food and Drug Administration
Mark Kaiser, Lancaster Laboratories
Michael Long, Dr.LP, Concordia Valsource
Judith Noble-Wang, Ph.D., Centers for Disease Control and Prevention
Per Arne Parment, M.D., Ph.D, Consultant
Dona Reber, Pfizer
David Roesti, Novartis
Frank Settineri, Consultant
Linda Skowronsry, GlaxoSmithKline
Donald Singer, GlaxoSmithKline
John Stone, Ph.D., Kao, USA
Scott Sutton, Ph.D., Microbiology Network, Inc.
Edward Tidswell, Ph.D., Baxter Healthcare
Myriam Sosa, Novartis

The content of this technical report represents a consensus and not necessarily the views of the organizations that employ the team members.
Exclusion of Objectionable Microorganisms from Nonsterile Pharmaceuticals, Medical Devices, and Cosmetics

Technical Report No. 67

ISBN: 978-0-939459-70-4
© 2014 Parenteral Drug Association, Inc.
All rights reserved.
Table of Contents

1.0 INTRODUCTION ................................................. 1
  1.1 Purpose ....................................................... 1
  1.2 Scope .......................................................... 1
    1.2.1 Exclusions ............................................... 2

2.0 GLOSSARY OF TERMS ......................................... 3

3.0 REGULATORY, COMPENDIAL AND SCIENTIFIC ENVIRONMENT .............................................. 5
  3.1 GMP .............................................................. 5
  3.2 Compendial Microbiological Testing ......................... 5
  3.3 Implications of the Human Microbiome Project.. 7
  3.4 Quality Risk Management .................................... 7

4.0 INDUSTRY BENCHMARKING .................................... 9

5.0 PRODUCT TYPES AND FORMULATION ...................... 11
  5.1 Microbial Risk Evaluation ................................... 11
  5.2 Hurdle Technology: Background ............................ 12
  5.3 Hurdle Technology in Product Development ............... 13
  5.4 Intermediate A\textsubscript{w} Formulations .............. 15
  5.5 High A\textsubscript{w} Formulations .......................... 15
  5.6 Risk Assessment of the Manufacturing Processes of Pharmaceutical, Medical Device and Cosmetic Ingredients and their Use in Nonsterile Products 16
  5.7 Preservative Systems in Nonsterile Pharmaceutical and OTC Drug Products 18
  5.8 Packaging Considerations for Nonsterile Product Dosage Forms ........................................ 20
    5.8.1 Package Design, Material, Construction and Function .............................................. 22
    5.8.2 Manner and Site of Application Based on the Package .................................................. 23
    5.8.3 Frequency and Duration of Product Package Use ......................................................... 24
    5.8.4 Environment Under Which the Product Package is Used and Stored ............................... 24

6.0 MITIGATING RISK THROUGH PROCESS DESIGN, MANUFACTURING AND PACKAGING OPERATIONS ......................................................... 26
  6.1 Manufacturing Process Equipment .......................... 26
  6.2 Basic Hygienic Designs of Process Equipment .......... 26
  6.3 Preventative Maintenance ..................................... 27
  6.4 Cleaning and Sanitization Practices ........................ 27
    6.4.1 Cleaning In Place ......................................... 28
    6.4.2 Choosing Detergents .................................. 29
    6.4.3 Draining and Drying of Equipment .................... 31
  6.5 Manufacturing Processes and Microbial Content ......... 31

7.0 LABORATORY TESTING — MICROBIAL ENUMERATION, DETECTION AND IDENTIFICATION ......................................................... 33
  7.1 General Testing Requirements .............................. 33
  7.2 Regulatory Requirements and their Relationship to Compendial Methods ........................................ 34
  7.3 Inconsistencies and Contradictions Among USP/NF Monographs ........................................ 35
  7.4 Laboratory Testing for Microbial Enumeration, Absence of Specified Microorganisms and Microbial Identification ........................................ 35
    7.4.1 USP/EP/JP Harmonized Chapters <61>, <62>, and <1111> ............................................ 35
  7.4.2 Chinese Pharmacopoeia Appendix XI J – Microbial Limit Tests .................................. 36
  7.4.3 Chapter 23, “Microbiological Methods for Cosmetics,” of the FDA’s BAM ................................ 37
  7.4.4 Cosmetics Toiletries & Fragrance Association Methods for Microbial Content and Examination for S. aureus, E. coli and P. aeruginosa ........................................ 38
  7.4.5 ISO Standards ............................................... 38
  7.4.6 Microbial Identification .................................... 40
  7.5 Screening for Objectionable Microorganisms .......... 41
  7.5.1 Laboratory Management Recommendation to the Quality Unit for Batch Release .................. 42
  7.6 Sample Handling, Transportation and Storage ........ 43

8.0 CLINICAL CONSIDERATIONS FOR SELECTING ISOLATES FOR ASSESSMENT OF THEIR STATUS AS OBJECTIONABLE OR NOT ........................................ 44
  8.1 Microorganisms Associated with Product Recalls .......................................................... 44
  8.2 Microorganisms Associated with Clinically Significant Infections ........................................ 44
  8.3 Microorganisms Associated with Outbreak Investigations by the Centers for Disease Control and Prevention .......................................................... 45
  8.4 Burkholderia cepacia Complex ................................ 48
  8.5 Pathogens Listed by Research Organizations, Regulatory Agencies and Authors of Prominent Microbiology Textbooks ........................................... 49

9.0 RISK ASSESSMENT AND MITIGATION ................... 51
  9.1 Risk-Based Approaches ....................................... 51
  9.2 Risk Assessment .................................................. 51
    9.2.1 Determination of Isolate’s Novelty .................. 51
    9.2.2 Determination of Known Pathogenicity .......... 52
    9.2.3 Assessment of Survivorship ............................ 52
    9.2.4 Determination of Product or Container Impact........ 52
1.0 Introduction

The exclusion of objectionable microorganisms from nonsterile healthcare products is a challenge for companies because it can be viewed as an undefined critical quality attribute. All other chemical, physical and microbiological attributes (e.g. potency, content variability, microbial count) are defined by test methods and product specifications, whereas the exclusion of objectionable microorganisms is poorly defined. This consensus industry document was developed by representatives of the pharmaceutical, medical device and cosmetic industries, academia and regulatory agencies and provides guidance to stakeholders, including industry representatives and regulators, to address these issues.

1.1 Purpose

The purpose of this technical report is to provide guidance to the nonsterile product manufacturing industry on how to manage the microbial risks associated with manufacturing and storage and how to determine what isolates would be deemed an objectionable microorganism in nonsterile products that is in alignment with the microbial limits requirements for releasing these products into the marketplace. Nonsterile products exceeding the microbial count limit and/or containing specified microorganisms for their product type would be expected to be rejected. Specified microorganisms include microorganisms with compendial requirements to be absent in a particular dosage form, and/or required by a national board of health to be excluded from a registered non-sterile product.

The contamination of marketed products by potentially objectionable microorganisms continues to be an infrequent but chronic problem. A U.S. survey of reported microbiologically related recalls between 2004 and 2011 found that 72% of recalls of nonsterile products were associated with objectionable microorganisms rather than exceeding microbial enumeration limits (1). Of the 144 recalls for nonsterile products, 5% involved nonsterile pharmaceutical drug products, 42% were for OTC drug products, 31% were for cosmetics, 14% were for medical devices and 8% were for dietary supplements. The average rate of reported recalls is 20 per year.

1.2 Scope

The scope of this technical report is the exclusion of objectionable microorganisms from nonsterile pharmaceutical drug products, over-the-counter (OTC) drug products; medical devices; cosmetics; and personal care products in the pharmaceutical, medical device, cosmetics and consumer healthcare industries (referred to as “our industry” in the remainder of this report). Objectionable microorganisms for nonsterile products, as cited in the U.S. Code of Federal Regulations (CFR) Title 21, Part 211.113, are microorganisms whose growth or persistence in nonsterile products can cause harm to users of those products and degrade the physicochemical, functional and/or therapeutic attributes of the products (2).

Since all viable microorganisms are excluded from sterile products, the term “objectionable microorganism” is used to refer only to nonsterile products. Some discussion of microorganisms contaminating sterile products and food may be included in this report for informational purposes, but, in general, such discussion is out of scope for the technical report.

This report provides the following information:

- References to literature on microbial contamination of nonsterile products
- Product types and their formulations as these relate to microbial contamination
- Manufacturing and packaging design and control
- Microbial enumeration, detection and identification
- Clinical aspects of objectionable microorganisms
- Risk assessment and mitigation